P936: Time to Response, Duration of Response, and Patient-Reported Outcomes With Daratumumab Plus Rd vs Rd Alone in Transplant-Ineligible Patients With Ndmm: Subgroup Analysis of the Phase 3 Maia Study

Facon, T.; Kumar, S. K.; Plesner, Torben; Moreau, P.; Bahlis, Nizar J.; Goldschmidt, H.; O’Dwyer, Michael; Perrot, A.; Venner, Chris; Weisel, Katja; Mace, Joseph R.; Tiab, Mourad; Macro, M.; Frenzel, L.; Leleu, Xavier; Pei, H.; Borgsten, F.; Usmani, S. Z.

doi:10.1097/01.hs9.0000846612.13339.9e

HemaSphere

2022

DOI: 10.1097/01.hs9.0000846612.13339.9e

|View full text |Cite

P936: Time to Response, Duration of Response, and Patient-Reported Outcomes With Daratumumab Plus Rd vs Rd Alone in Transplant-Ineligible Patients With Ndmm: Subgroup Analysis of the Phase 3 Maia Study

T. Facon

S. K. Kumar

Torben Plesner

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant

Langer,

John,

Monsef

et al. 2024

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant

Langer,

John,

Monsef

et al. 2024

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

P936: Time to Response, Duration of Response, and Patient-Reported Outcomes With Daratumumab Plus Rd vs Rd Alone in Transplant-Ineligible Patients With Ndmm: Subgroup Analysis of the Phase 3 Maia Study

Cited by 1 publication

References 0 publications

Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant

Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant

Contact Info

Product

Resources

About